A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.
The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.
The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.
Clariant and Huntsman announce $20 billion 'Merger of Equals.'
Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating